{
    "nct_id": "NCT03397173",
    "official_title": "Targeting TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia (AML) With Azacitidine and Ascorbic Acid",
    "inclusion_criteria": "* Patients must have a confirmed heterozygous TET2 mutations identified by next generation targeted deep sequencing.\n* Patients must have MDS, or MDS/MPN overlap defined by 2016 World Health Organization (WHO) criteria. Both newly diagnosed or previously treated MDS or MDS/MPN patients are eligible as long as the patient has never received prior treatment with azacitidine or decitabine.\n* Patients with Leukemic/blast phase transformation MPN.\n* Patient with AML according to 2016 WHO criteria.\n\n  * Newly diagnosed patients who are ineligible or declined to receive intensive chemotherapy after discussion of risks and benefits of that approach or patients with primary refractory/relapsed AML.\n  * Patients with active central nervous system (CNS) leukemia eligible at the discretion of treating physician.\n  * Relapse/Refractory is defined as at least 1 course of treatment for AML excluding any patients treated with azacitidine or decitabine.\n\n    * Patients should be off any prior treatment or line of therapy for 2 weeks prior to start study with the exception of hydrea (Hydroxyurea).\n* Prior therapy with hydroxyurea, biological or targeted therapy (e.g. flt3 inhibitors, other kinase inhibitors) or hematopoietic growth factors is allowed.\n* Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 3.\n* Patients must have normal organ and marrow function as defined at the discretion of the treating physician and PI.\n* Women of childbearing potential must have a negative serum or urine pregnancy test within 10-14 days prior to enrollment.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document.\n* Patient must be willing to comply with all aspects of the protocol including completing the drug diary.\n* Patient must discontinue any and all use of multivitamin and/or vitamin c medication 24 hours before first dose of Ascorbic Acid.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any prior treatment with azacitidine or decitabine.\n* Patients diagnosed with acute promyelocytic leukemia (APL), AML-M3.\n* Patients receiving other active treatment for their myeloid malignancy including investigational agents with the exception of hydrea for white blood cell control.\n* Nursing or pregnant women.\n* History of allergic reactions to either azacitidine or ascorbic acid.\n* Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Patients with higher risk of bleeding (deemed by the treating physician) or on anticoagulation.\n* Patients who are unwilling or unable to comply with all study requirements.",
    "miscellaneous_criteria": ""
}